ClinicalTrials.gg
CompletedNCT07741591PASSUpdated Nov 17, 2026

Impact of Perioperative Antibiotic Use on Surgical Scarring

An observational study in Surgical Scar and Postoperative Scar, sponsored by Nanfang Hospital, Southern Medical University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,744
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Cicatrix with a site in China — 8 open to participants now, 8 under way, none of them phase 3. Cicatrix · China.

Started
2026
with 3 others
Observational
8 of 42
1 open now
Registered
39th of 42
by date

Among the 42 studies in Cicatrix with a site in China, this one is one of 4 that started in 2026, is one of 8 observational ones, and was the 39th registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

8 of the 42 studies in Cicatrix with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Cicatrix with a site in China, or all of them as a file.
02

Study summary

This retrospective observational cohort study will evaluate whether perioperative antibiotic use is associated with long-term surgical scar outcomes. The study will include adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025 and have available surgical, medication, and scar-related clinical records.

The study will not assign participants to any treatment. Researchers will review existing medical records, perioperative antibiotic exposure, surgical characteristics, complications, and scar assessments or photographs. Scar outcomes will be assessed using modified visual analogue scale scores, scar width, scar type, and scar-related complications.

03

Conditions studied

  • Surgical Scar
  • Postoperative Scar

Browse trials for

Keywords

  • Perioperative Antibiotics
  • Surgical Scar
  • Postoperative Scar
  • Scar Assessment
  • Visual Analogue Scale
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025, developed a linear surgical incision scar, and later presented to the Department of Plastic Surgery for scar-related care. Eligible patients must have available surgical records, perioperative medication records, and scar outcome information.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025, with a linear surgical incision scar.
  • Presented to the Department of Plastic Surgery at Nanfang Hospital for surgical scar-related care.
  • Had no medical encounter record at Nanfang Hospital from January 1, 2025 to the time of study screening.
  • Available clear surgical records and perioperative medication records.

Exclusion criteria

Exclusion Criteria:

  • Known tendency for pathological scarring or scar constitution.
  • History of chronic skin disease in the surgical area, such as psoriasis or eczema.
  • Uncontrolled diabetes mellitus, malnutrition, hypoalbuminemia, or long-term use of agents or .
  • Target scar received any scar-specific treatment after surgery, such as laser therapy, radiotherapy, drug injection, or surgical revision.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,744 participants (actual)
Patient registry
No

Groups and cohorts

  • Retrospective Surgical Scar Cohort

    Adult patients who underwent body surface surgery at Nanfang Hospital between January 1, 2005 and January 1, 2025 and have available surgical records, perioperative medication records, and scar outcome information.

    Other: Perioperative Antibiotic Exposure

Interventions

  • OtherPerioperative Antibiotic Exposure

    Patterns of perioperative antibiotic use documented in existing medical records, including timing, indication, antibiotic type, duration, frequency, and route of administration. No antibiotic treatment will be assigned or provided by the study.

06

What researchers measure

Primary outcomes

  1. Overall Scar Appearance Score Assessed Using a Modified Visual Analogue Scale

    Overall scar appearance will be evaluated from scar photographs by three blinded physicians or trained study personnel using a modified visual analogue scale. Scores range from 1 to 10, with 1 indicating appearance similar to normal skin and 10 indicating the worst imaginable scar appearance.

    Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam

Secondary outcomes

  1. Scar Color Score Assessed Using a Modified Visual Analogue Scale

    Scar color will be evaluated from scar photographs by three blinded physicians or trained study personnel using a modified visual analogue scale. Scores range from 1 to 10, with lower scores indicating color more similar to normal skin and higher scores indicating worse scar color.

    Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam

  2. Scar Texture Score Assessed Using a Modified Visual Analogue Scale

    Scar texture will be evaluated from scar photographs by three blinded physicians or trained study personnel using a modified visual analogue scale. Scores range from 1 to 10, with lower scores indicating texture more similar to normal skin and higher scores indicating worse scar texture.

    Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam

  3. Scar Width

    Scar width will be calculated from scar photographs by outlining the scar boundary and using ImageJ to measure scar area and scar length. Scar width will be calculated as scar area divided by scar length.

    Time frame: Scar photographs were taken during postoperative clinical follow-up, with an overall range from 3 months to 20 years after surgery. Given the wide span, the assessments will be stratified and reported according to the actual time of photography, for exam

  4. Scar-Related Complications

    Scar-related complications will be identified from medical records and scar assessments, including wound dehiscence, suture reaction, necrosis, hematoma, infection, persistent itching, persistent pain, and sensory abnormalities.

    Time frame: Postoperative days 0 to 30 (inclusive). The timing of each complication was determined from medical records.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2026 to primary completion in Oct 2026, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Aug 2026 → Oct 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Aug 3, 2026
StartActual
Aug 3, 2026
Primary completionActual
Oct 15, 2026was Aug 2026
CompletionActual
Nov 5, 2026was Aug 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 17, 2026
Primary completion
Aug 15, 2026→Oct 15, 2026 (actual)
Nov 17, 2026
Study completion
Aug 15, 2026→Nov 5, 2026 (actual)
Nov 17, 2026
Enrollment
5000 (estimated)→2744 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Completed
    Primary completion Aug 15, 2026→Oct 15, 2026 (now actual)
    Study completion Aug 15, 2026→Nov 5, 2026 (now actual)
    Enrollment 5000 (estimated)→2744 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07741591
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Aug 3, 2026
Primary completion
Oct 15, 2026
Completion
Nov 5, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion